# IgG Antibodies After SARS-CoV-2 mRNA Vaccine in Kidney Transplantation (TASMANIA)

> **NCT04832841** · — · COMPLETED · sponsor: **Institute for Clinical and Experimental Medicine** · enrollment: 753 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DIAGNOSTIC_TEST:** anti-spike SARS-CoV-2 IgG

## Key facts

- **NCT ID:** NCT04832841
- **Lead sponsor:** Institute for Clinical and Experimental Medicine
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-18
- **Primary completion:** 2021-09-30
- **Final completion:** 2022-03-30
- **Target enrollment:** 753 (ACTUAL)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04832841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04832841, "IgG Antibodies After SARS-CoV-2 mRNA Vaccine in Kidney Transplantation (TASMANIA)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04832841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*